Pancreatic cancer is one of the deadliest cancers. Even with aggressive treatment, the prognosis is poor. Various factors stack the odds against successful pancreatic cancer treatment:
- Early detection is uncommon. Few pancreatic cancers are found in the early stages of the disease, when the cancerous cells can be surgically removed. Signs and symptoms of pancreatic cancer — such as pain in the upper abdomen, yellow skin and eyes, and weight loss — don't typically occur until the disease is advanced.
- Pancreatic cancer tends to spread quickly. The pancreas lies at the junction of several very important structures in your abdomen, making it easy for the cancer to spread into these structures and organs. Pancreatic cancer often spreads to nearby organs — including the liver, gallbladder and intestines — early in the course of the disease.
- Recurrence is likely. Even after surgical removal, pancreatic cancer often recurs.
In addition, pancreatic cancer tends to be relatively resistant to chemotherapy. However, several newer treatments show promise in increasing the response rate to pancreatic cancer treatment.
Aug. 07, 2013
- Fernandez-del Castillo C. Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer. http://www.uptodate.com/home. Accessed June 19, 2013.
- Ryan DP, et al. Management of locally advanced and borderline resectable exocrine pancreatic cancer. http://www.uptodate.com/home. Accessed June 19, 2013.
- Ryan DP. Chemotherapy for advanced exocrine pancreatic cancer. http://www.uptodate.com/home. Accessed June 18, 2013.
- Pancreatic cancer. American Cancer Society. http://www.cancer.org/cancer/pancreaticcancer/detailedguide/pancreatic-cancer-new-research. Accessed June 19, 2013.
- Diep CH, et al. Synergistic effect between erlotinib and MEK inhibitors in KRAS wildtype human pancreatic cancer cells. Clinical Cancer Research. 2011;17:2744.
- Lange F, et al. Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach. World Journal of Gastroenterology. 2012;18:6226.
- FDA approval for erlotinib hydrochloride. National Cancer Institute. http://www.cancer.gov/cancertopics/druginfo/fda-erlotinib-hydrochloride#Anchor-Pancreati-44285. Accessed June 19, 2013.
- Conroy T, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England Journal of Medicine. 2011;364:1817.